FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783006274> ?p ?o ?g. }

• W2783006274 abstract "H1/IC31® is a tuberculosis (TB) subunit vaccine candidate consisting of the fusion protein of Ag85B and ESAT-6 (H1) formulated with the IC31® adjuvant. Previous trials have reported on the H1/IC31® vaccine in M. tuberculosis (Mtb)-naïve, BCG-vaccinated and previously Mtb-infected individuals. In this trial, conducted between December 2008 and April 2010, the safety and immunogenicity of H1/IC31® was assessed in participants living in Ethiopia – a highly TB-endemic area. Healthy male participants aged 18–25 years were recruited into four groups. Participants in group 1 (N = 12) and group 2 (N = 12) were Tuberculin Skin Test (TST) negative and QuantiFERON-TB Gold in-tube test (QFT) negative (Mtb-naïve groups), participants in group 3 (N = 3) were TST positive and QFT negative (BCG group), and participants in group 4 (N = 12) were both TST and QFT positive (Mtb-infected group). H1 vaccine alone (group 1) or H1 formulated with the adjuvant IC31® (groups 2, 3 and 4) was administered intramuscularly on day 0 and day 56. Safety and immunogenicity parameters were evaluated for up to 32 weeks after day 0. The H1/IC31®vaccine was safe and generally well tolerated. There was little difference among the four groups, with a tendency towards a higher incidence of adverse events in Mtb-infected compared to Mtb-naïve participants. Two serious adverse events were reported in the Mtb-infected group where a relationship to the vaccine could not be excluded. In both cases the participants recovered without sequelae within 72 h. Immunogenicity assays, evaluated in the 29 participants who received both vaccinations, showed a stronger response to TB antigens in the Mtb-naïve group vaccinated with the adjuvant. The trial confirmed the need for an adjuvant for the vaccine to be immunogenic and highlighted the importance of early phase testing of a novel TB vaccine candidate in TB-endemic areas. ClinicalTrials.gov, ID: NCT01049282. Retrospectively registered on 14 January 2010." @default.
• W2783006274 created "2018-01-26" @default.
• W2783006274 creator A5000009266 @default.
• W2783006274 creator A5006649234 @default.
• W2783006274 creator A5021216969 @default.
• W2783006274 creator A5040511970 @default.
• W2783006274 creator A5051006766 @default.
• W2783006274 creator A5051884351 @default.
• W2783006274 creator A5055747967 @default.
• W2783006274 creator A5056105353 @default.
• W2783006274 creator A5074953709 @default.
• W2783006274 creator A5076641544 @default.
• W2783006274 creator A5077331555 @default.
• W2783006274 creator A5078003599 @default.
• W2783006274 creator A5080578571 @default.
• W2783006274 creator A5088437387 @default.
• W2783006274 creator A5090470995 @default.
• W2783006274 date "2018-01-10" @default.
• W2783006274 modified "2023-10-02" @default.
• W2783006274 title "A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area" @default.
• W2783006274 cites W1874659400 @default.
• W2783006274 cites W1977575192 @default.
• W2783006274 cites W1982940534 @default.
• W2783006274 cites W1983763479 @default.
• W2783006274 cites W2006091616 @default.
• W2783006274 cites W2012456730 @default.
• W2783006274 cites W2022775561 @default.
• W2783006274 cites W2035214942 @default.
• W2783006274 cites W2058969608 @default.
• W2783006274 cites W2066751520 @default.
• W2783006274 cites W2073311979 @default.
• W2783006274 cites W2086707243 @default.
• W2783006274 cites W2098979666 @default.
• W2783006274 cites W2116619718 @default.
• W2783006274 cites W2127558739 @default.
• W2783006274 cites W2127681731 @default.
• W2783006274 cites W2137780892 @default.
• W2783006274 cites W2165418498 @default.
• W2783006274 cites W25116345 @default.
• W2783006274 cites W2556974178 @default.
• W2783006274 cites W4205161959 @default.
• W2783006274 cites W926099720 @default.
• W2783006274 doi "https://doi.org/10.1186/s13063-017-2354-0" @default.
• W2783006274 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5764015" @default.
• W2783006274 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29321075" @default.
• W2783006274 hasPublicationYear "2018" @default.
• W2783006274 type Work @default.
• W2783006274 sameAs 2783006274 @default.
• W2783006274 citedByCount "19" @default.
• W2783006274 countsByYear W27830062742018 @default.
• W2783006274 countsByYear W27830062742019 @default.
• W2783006274 countsByYear W27830062742020 @default.
• W2783006274 countsByYear W27830062742021 @default.
• W2783006274 countsByYear W27830062742022 @default.
• W2783006274 countsByYear W27830062742023 @default.
• W2783006274 crossrefType "journal-article" @default.
• W2783006274 hasAuthorship W2783006274A5000009266 @default.
• W2783006274 hasAuthorship W2783006274A5006649234 @default.
• W2783006274 hasAuthorship W2783006274A5021216969 @default.
• W2783006274 hasAuthorship W2783006274A5040511970 @default.
• W2783006274 hasAuthorship W2783006274A5051006766 @default.
• W2783006274 hasAuthorship W2783006274A5051884351 @default.
• W2783006274 hasAuthorship W2783006274A5055747967 @default.
• W2783006274 hasAuthorship W2783006274A5056105353 @default.
• W2783006274 hasAuthorship W2783006274A5074953709 @default.
• W2783006274 hasAuthorship W2783006274A5076641544 @default.
• W2783006274 hasAuthorship W2783006274A5077331555 @default.
• W2783006274 hasAuthorship W2783006274A5078003599 @default.
• W2783006274 hasAuthorship W2783006274A5080578571 @default.
• W2783006274 hasAuthorship W2783006274A5088437387 @default.
• W2783006274 hasAuthorship W2783006274A5090470995 @default.
• W2783006274 hasBestOaLocation W27830062741 @default.
• W2783006274 hasConcept C120665830 @default.
• W2783006274 hasConcept C121332964 @default.
• W2783006274 hasConcept C126322002 @default.
• W2783006274 hasConcept C142724271 @default.
• W2783006274 hasConcept C147483822 @default.
• W2783006274 hasConcept C197934379 @default.
• W2783006274 hasConcept C203014093 @default.
• W2783006274 hasConcept C22070199 @default.
• W2783006274 hasConcept C2776247216 @default.
• W2783006274 hasConcept C2777863537 @default.
• W2783006274 hasConcept C2777975735 @default.
• W2783006274 hasConcept C2778288313 @default.
• W2783006274 hasConcept C2779078216 @default.
• W2783006274 hasConcept C2780868878 @default.
• W2783006274 hasConcept C2781069245 @default.
• W2783006274 hasConcept C61511704 @default.
• W2783006274 hasConcept C71924100 @default.
• W2783006274 hasConceptScore W2783006274C120665830 @default.
• W2783006274 hasConceptScore W2783006274C121332964 @default.
• W2783006274 hasConceptScore W2783006274C126322002 @default.
• W2783006274 hasConceptScore W2783006274C142724271 @default.
• W2783006274 hasConceptScore W2783006274C147483822 @default.
• W2783006274 hasConceptScore W2783006274C197934379 @default.
• W2783006274 hasConceptScore W2783006274C203014093 @default.
• W2783006274 hasConceptScore W2783006274C22070199 @default.
• W2783006274 hasConceptScore W2783006274C2776247216 @default.
• W2783006274 hasConceptScore W2783006274C2777863537 @default.
• W2783006274 hasConceptScore W2783006274C2777975735 @default.

• next